Harmony Biosciences Holdings Inc
Closed
SectorHealthcare
41.21 0.37
Overview
Share price change
24h
Min
40.65
Max
41.67
Income | 43M 75M |
|---|---|
Sales | 46M 261M |
P/E Sector Avg | 13.673 56.597 |
EPS | 1.28 |
Profit margin | 28.87 |
Employees | 293 |
EBITDA | 53M 102M |
Next Earnings | 3 lis 2026 |
|---|
Market Cap | 400M 2.5B |
|---|---|
Previous open | 40.84 |
Previous close | 41.21 |
News Sentiment
By Acuity
67%
33%
289 / 339 Ranking in Healthcare
Harmony Biosciences Holdings Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Harmony Biosciences Holdings Inc Forecast
Sentiment
By Acuity
289 / 339 Ranking in Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.